The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01E | Protein kinase inhibitors | |
| 4 | L01EG | Mammalian target of rapamycin (mTOR) kinase inhibitors | |
| 5 | L01EG02 | Everolimus |
| Active Ingredient | Description | |
|---|---|---|
| Everolimus |
Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity of which is known to be upregulated in a number of human cancers. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| AFINITOR Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VOTUBIA Dispersible tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VOTUBIA Tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
